Media resources

Media

Access media assets, breaking news, press releases, and scientific publications

Explore this page for media resources, including a press kit, current news, and press releases. To sign up for breaking news alerts, register here. For media inquiries, please contact us at Media@Akebia.com.

Media kit

Includes logos, leadership photography and bios

Download all media kit assets (ZIP file, 5.5 MB)


Akebia logo

ZIP (285KB)

Akebia logo (white/knockout)

ZIP (617KB)


John Butler (President and CEO) photos and biography

Portrait

Hi-res JPG (402KB)

Full-length

Hi-res JPG (1MB)

Candid

JPG (72KB)

Biography

PDF Biography (145KB)


Recent press releases

Thursday, May 25, 2017
Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer

Wednesday, May 24, 2017
Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents

Monday, May 15, 2017
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

View all press releases »


Featured news articles

Monday, November 3, 2014
BioCentury: Full Steam Ahead

Wednesday, June 9, 2014
Xconomy: Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race

Friday, March 21, 2014
CNBC – Squawk on the Street: Akebia IPO Highlighted

View all news articles »


Recent publications

2015 ASN: Posters
Vadadustat Demonstrates Controlled Hemoglobin Response in a Phase 2b Study for the Treatment of Anemia in Patients with Non-Dialysis Dependent Chronic Kidney Disease

Dose Exposure Relationship of Vadadustat is Independent of the Level of Renal Function

Vadadustat, a Novel, Oral Treatment for Anemia of CKD, Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from Erythropoiesis-Stimulating Agents

2014 ASN: Posters
Phase 2 Study of AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD)

Hemodialysis has minimal impact on the pharmacokinetics of AKB-6548, a once-daily oral inhibitor of hypoxia-inducible factor prolyl-hydroxylases (HIF-PHs) for the treatment of anemia related to chronic kidney disease (CKD)

View all publications »